Sort   by:  
 Page size 
UnknownSafety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.
Not available
S-EPMC11016890 | biostudies-literature
UnknownBRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.
Not available
S-EPMC6286161 | biostudies-literature
UnknownPemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Not available
S-EPMC8461541 | biostudies-literature
UnknownPancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.
Not available
S-EPMC10898186 | biostudies-literature
UnknownImmunotherapy in Advanced Biliary Tract Cancers.
Not available
S-EPMC8036747 | biostudies-literature
UnknownA first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Not available
S-EPMC8426237 | biostudies-literature
UnknownResolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota.
Not available
S-EPMC7768083 | biostudies-literature
UnknownSaturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Not available
S-EPMC12807871 | biostudies-literature
UnknownNotch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia.
Not available
S-EPMC12317248 | biostudies-literature
UnknownPD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer.
Not available
S-EPMC9235886 | biostudies-literature
Sort   by:  
 Page size